WO1991005796A1 - Carboxyalkyl dipeptide inhibitors of endopeptidases - Google Patents
Carboxyalkyl dipeptide inhibitors of endopeptidases Download PDFInfo
- Publication number
- WO1991005796A1 WO1991005796A1 PCT/US1990/005640 US9005640W WO9105796A1 WO 1991005796 A1 WO1991005796 A1 WO 1991005796A1 US 9005640 W US9005640 W US 9005640W WO 9105796 A1 WO9105796 A1 WO 9105796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- aryl
- hydroxy
- formula
- Prior art date
Links
- 0 CCC1*(CC)N(*C(*)NC(*)CC(C)(*)[Xe])C(*)C1 Chemical compound CCC1*(CC)N(*C(*)NC(*)CC(C)(*)[Xe])C(*)C1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Definitions
- the present invention relates to carboxyalkyl dipeptide inhibitors of endopeptidases useful in the treatment of cardiovascular disorders and pain
- Cardiovascular conditions which may be treated with compounds of the present invention include
- Human hypertension represents a disease of multiple etiologies. Included among these is a sodium and volume dependent low renin form of hypertension.
- Drugs that act to control one aspect of hypertension will not necessarily be effective in controlling another.
- Enkephalin is a natural opiate receptor agonist which is known to produce a profound analgesia when injected into the brain ventricle of rats. It is also known in the art that enkephalin is acted upon by a group of enzymes known as enkephalinases or endopeptidases, which are also naturally occurring, and is inactivated thereby.
- R 5 in the cited patent may be a variety of alkyl or amino derivatives or a heterocyclic.
- R 1 is preferably hydrogen or phenyl and R 2 is preferably hydrogen, alkyl, benzyl or benzyloxyalkyl.
- the compounds are said to have enkephalinase inhibiting and hypotensive activity.
- R 1 and R 3 are preferably phenylethyl and R 4 is preferably hydrogen, methyl or benzyl.
- German Patent Application 3,819,539, published December 22, 1988 discloses, inter alia, carboxyalkyl compounds of the formula
- R 1 and R 8 are preferably benzyl and R 5 is preferably hydrogen or lower alkyl.
- Atrial natriuretic factors ANF which help.to regulate blood pressure, blood volume and the excretion of water, sodium and potassium.
- ANF atrial natriuretic factors
- ACE inhibitors which compounds are useful in blocking the rise in blood pressure caused by increases in vascular resistance and fluid volume due to the formation of angiotensin II from angiotensin I.
- ACE Inhibitors see M. wyvratt and A. Patchett, "Recent Developments in the Design of Angiotensin Converting Enzyme Inhibitors" in Med. Res. Rev. Vol. 5, No. 4 (1985) pp. 483-531.
- Novel compounds of the present invention are represented by the formula
- R 1 is H, alkyl, arylalkyl or aryl
- R 2 is H, alkyl, alkenyl or alkynyl, wherein the alkyl portion is substituted with 0-3 substituents
- R 3 and-R 4 are independently alkyl or arylalkyl; or R 3 and R 4 together with the carbon to which they are attached form a 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group consisting of sulfur and oxygen, wherein said ring is unsubstituted or is substituted on a carbon atom ring member by an alkyl or aryl group, or wherein said ring is substituted by a fused benzene ring;
- R 5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl;
- R 6 is H, hydroxy, alkoxy, alkyl, alkoxyalkyl
- alkylthioalkyl arylalkoxyalkyl, arylalkylthioalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl;
- R 7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino;
- n 0 or 1
- n 0, 1, 2 or 3;
- a preferred group of compounds of the present invention is that wherein R 2 is arylalkyl, especially phenylethyl. Another preferred group is that wherein R 3 and R 4 together with the carbon to which they are
- the invention also relates to the treatment of cardiovascular diseases with a combination of a
- carboxyalkyl dipeptide of the present invention and an atrial natriuretic factor (ANF) or with a combination of a carboxyalkyl dipeptide of the present invention and an angiotensin converting enzyme (ACE) inhibitor.
- ANF atrial natriuretic factor
- ACE angiotensin converting enzyme
- compositions comprising a carboxyalkyl dipeptide of this invention, alone or in combination with an ANF or an ACE inhibitor, and to methods of treatment of cardiovascular diseases comprising administering a carboxyalkyl dipeptide of this invention, alone or in combination with an ANF or an ACE inhibitor, to a mammal in need of such treatment.
- Still another aspect of this invention relates to a method of treating pain conditions by administering a carboxyalkyl dipeptide of this invention, thereby inhibiting the action of endopeptidases in a mammal and eliciting an analgesic effect.
- Analgesic pharmaceutical compositions comprising said carboxyalkyl dipeptide compounds are also contemplated.
- alkyl means straight or branched lower alkyl chains of 1 to 6 carbon atoms; "alkenyl” similarly means lower alkenyl chains of 2 to 6 carbon atoms; “alkynyl” means lower alkynyl chains of 2 to 6 carbon atoms; and “alkoxy” similarly means lower alkoxy chains of 1 to 6 carbon atoms.
- Aryl means a phenyl or. naphthyl ring; a phenyl or naphthyl ring substituted with 1-3 substituents selected from the group consisting of alkyl, hydroxy. alkoxy, halo, trifluoromethyl, phenyl, phenoxy and phenylthio; or a phenyl ring wherein adjacent alkyl or alkyl and alkoxy substituents form a 5- or 6-membered ring (for example indanyl, dihydrobenzofuranyl,
- Heteroaryl means mono-cyclic or fused ring bicyclic aromatic groups having 5 to 10 ring members wherein 1-2 ring members are independently selected from the group consisting of oxygen, nitrogen and sulfur and wherein 1-3 carbon ring members may be substituted with substituents as defined above for aryl.
- heteroaryl groups are furanyl, thienyl, pyrrolyl, benzofuranyl, thianaphthenyl, indolyl and pyridyl.
- Halo means fluoro, chloro, bromo or iodo radicals.
- acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art.
- Certain compounds of the invention are acidic e.g., those compounds which possess a carboxyl group.
- salts with inorganic and organic bases.
- examples of such salts are the sodium, potassium, calcium and aluminum salts.
- salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxy alkyl amines, N-methylglucamine and the like.
- the salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is
- Compounds of formula I have at least one asymmetrical carbon atom and therefore include various stereoisomers.
- the invention includes all such isomers both in pure form and in admixture, including racemic mixtures.
- An aspect of the present invention described above relates to the combination of a compound of formula I with an ANF.
- ANF As indicated by Needleman et al., a number of ANF have been isolated so far, all having the same core sequence of 17 amino acids within a cysteine disulfide bridge, but having different N-termini
- peptides represent N-terminal truncated fragments (21-48 amino acids) of a common preprohormone (151 and 152 amino acids for man and rats, respectively).
- Human, porcine and bovine carboxy-terminal 28-amino acid peptides are identical and differ from similar peptides in rats and mice in that the former contain a methionine group at position 12 while the latter contain
- ANF's contemplated for use in this invention are ⁇ human AP 21 (atriopeptin I), o human AP 28, ⁇ human AP 23 (atriopeptin II or APII), a human AP 24, ⁇ human AP 25, ⁇ human AP 26, o human AP 33, and the corresponding rat sequence of each of the above wherein Met 12 is lie. See Table 1 for a comparison of the peptides.
- Another aspect of the invention is the administration of a combination of an ACE inhibitor and a compound of formula I.
- ACE inhibitors examples include those disclosed in the article by Wyvratt et al., cited above, and in the following U.S. patents: U.S. Patents 4,105,776,
- R b and R 9 b are OH, 1-6C alkoxy, 2-6C alkonyloxy, di-(1-6C alkyl) amino- (1-6C) alkoxy, 1-6C hydroxy alkoxy, acylamino-(1-6C) alkoxy, acyloxy-(1-
- R 7 b -R 5 b , R 7 b and R 8 b are 1-20C alkyl, 2-20C alkonyl,
- R 6 b is cycloalkyl, polycycloalkyl, partly saturated cycloalkyl or polycycloalkyl, cycloalkyl- (1-6C) alkyl having 3-20C, 6-10C aryl, aryl-(1-6C) alkyl, aryl-(2-
- partially unsaturated are optionally substituted by halogen, 1-6C hydroxy alkyl, 1-6C alkoxy, amino-(1-
- aryl groups are optionally substituted by OH, 1-6C alkoxy, NH 2 , mono- or di-(1-6C alkyl) amino, SH, 1-
- R b and R 9 b are H or 1-6C alkoxy
- R 1 b and R 2 b are H, 1-6C alkyl, aryl-(1-6C) alkyl having 7-12C or heterocyclyl-(1-6C) alkyl having 6-
- R 3 b -R 5 b , R 7 b and R 8 b are H or 1-6C alkyl
- R 6 b is cycloalkyl, polycycloalkyl, partly saturated cycloalkyl or polycycloalkyl, cycloalkyl-(1-6C) alkyl having 3-20C, aryl or aryl-(1-6C) alkyl; and aryl has 6-10C and is optionally substituted by 1-6C alkyl, 2-6C alkonyl, 2-6C alkynyl, OH, 1-6C alkoxy,
- NH 2 mono- or di-(1-6C alkyl) amino, SH, 1-6C alkylthio, 1-6C hydroxy alkyl, 1-6C aminoalkyl, 1-6C thioalkyl, NO 2 , halogen, CF 3 , OCH 2 O, ureido or guanidino;
- R c and R 6c are the same or different and are hydroxy, lower alkoxy, lower alkonyloxy, dilower alkylamino lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy, aryloxy, aryllower alkoxy, amino, lower alkylamino, dilower alkylamino, hydroxy amino, aryllower alkylamino, or substituted aryloxy or substituted aryllower alkoxy wherein the substituent is methyl, halo or methoxy; R 1c is hydrogen, alkyl of from 1 to 10 carbon atoms,
- substituted lower alkyl wherein the substituent is hydroxy, lower alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, amino, lower alkylamino, diloweralkylamino, acylamino, arylamino, substituted arylamino, guanidino, imidazolyl, indolyl, lower alkylthio, arylthio, substituted arylthio, carboxy, carbamoyl, lower alkoxy carboxyl, aryl, substituted aryl, aralkyloxy, substituted aralkyloxy, aralkylthio or substituted aralkylthio, wherein the aryl or heteroaryl portion of said substituted aryloxy, heteroaryloxy, arylamino, arylthio, aryl, aralkyloxy, aralkylthio group is substituted with a group selected from halo, lower alky
- R 2c and R 7c are the same or different and are hydrogen or lower alkyl;
- R 3c is hydrogen, lower alkyl, phenyl lower alkyl,
- R 4c and R 5c are the same or different and are hydrogen, lower alkyl or Z c , or R 4c and R taken together form a group represented by Q c , U c ,
- X 1c and X 2c independent of each other are O, S or CH 2
- R 8c and R 9c independent of each other are lower alkyl, lower alkonyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl, or -(CH 2 ) n c Ar c , wherein n c is 0, 1, 2 or 3 and Ar c is unsubstituted or substituted phenyl, furyl, thienyl or pyridyl, wherein said substituted phenyl, furyl, thienyl or pyridyl groups are substituted with at least one group that is
- W c is a single bond or a methylene bridge or a substituted methylene bridge when at least one of X 1c and X 2c is methylene, or W c is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms, said substituted methylene bridge or said substituted alkylene bridge having one or two substituents selected from lower alkyl, aryl and aryl lower alkyl groups, and p c is 0, 1 or 2; with the proviso that at least one of R 4c and R 5c is Z c , with the proviso that if R 4c is Z c and p c is 0 then X 1c and X 2c must both be methylene, and with the proviso that if X 1c and
- R 8c , R 9c , X 1c and X 2c are as defined above, p c is 0, 1 or 2, q c is 0, 1 or 2, with the proviso that the sum of p c and q c must be 1, 2 or 3, with the proviso that if p c is 0 then X 1c and X 2c must be methylene, and with the proviso that if X 1c and X 2c are methylene then R 8c and R 9c taken together form a bridge W c , wherein W c is as defined above; is
- R 8c , R 9c , X 1c and X 2c are as defined above, p c is 0, l or 2 and q c is 0, 1 or 2, with the proviso that the sum of p c and q c is 1, 2 or 3, with the proviso that if X 1c and X 2c are CH 2 then R 8c and R 9c taken together form a bridge W c , wherein W c is as defined above;
- W c is as defined above (except that W c may also be a methylene bridge when X 1c and X 2c are oxygen or sulfur), X 1c and X 2c are as defined above, p c is 0, 1 or 2, q c is 0, 1 or 2, with the proviso that the sum of p c and q c is 1 or 2, and with the proviso that if p c is 0, X 1c must be CH 2 ;
- G c is oxygen, sulfur or CH 2 , a c is 2, 3 or 4 and b c is 1, 2, 3, 4 or 5, with the proviso that the sum of a c and b c is 5, 6 or 7 or
- G c is CH 2 , a c is 0, 1, 2 or 3, b c is 0, 1, 2 or 3 with the proviso that the sum of a c and b c is 1, 2 or 3, with the proviso that the sum of a c and b c may be 1, 2 or 3 only if R 1c is lower alkyl substituted with aralkylthio or aralkyloxy;
- F c is 0 or S
- -j c is 0, 1 or 2
- k c is 0, 1 or 2
- m c is 1, 2 or 3
- t c is 1, 2 or 3, with the proviso that the sum of m c and t c must be 2, 3 or 4;
- R d and R 2d are independently hydrogen; loweralkyl; aralkyl; or aryl;
- R 1 is hydrogen; branched or straight chain C 1-12 alkyl and alkonyl; C 3 -C 9 cycloalkyl and benzofused alkyl; substituted loweralkyl where the substituents are halo, hydroxy loweralkoxy, aryloxy, amino, mono- or diloweralkylamino, acylamino, arylamino,
- heteroarloweralkenyl where the aryl and heteroaryl substituents are halo, dihalo, loweralkyl, hydroxy, loweralkoxy, amino, aminoloweralkyl, acylamino. mono- or diloweralkylamino, carboxyl,
- haloloweralkyl nitro, cyano, or sulfonamido, and where the loweralkyl portion of arloweralkyl may be substituted by amino, acylamino, or hydroxyl;
- X d and Y d taken together are -CH 2 -CH 2 -;
- R 4d is hydrogen; loweralkyl; aryl; substituted aryl; R 5d is hydrogen; loweralkyl; aryl or substituted aryl; n d is 1 to 3;
- W d is absent; -CH 2 -; or
- Z d is -(CH 2 ) m d , where m d is 0 to 2, provided that m d may not be 0 and W d may not be absent at the same time;
- R 6d is hydrogen; loweralkyl; halo; or OR 4d ;
- R 2d is ___ (CH 2 ) r d____ B d ___ (CH 2 ) s d ____ NR 7d R 15d where
- r d and s d are independently 0 to 3;
- B d is absent; -O-; -S-; or -NR 8d ;
- R 8d is hydrogen; loweralkyl; alkanoyl; or aroyl
- R 9d is loweralkyl; aralkyl; aryl; heteroaryl; or
- heteroarloweralkyl and these groups substituted by hydroxy, lower alkoxy or halo; carboxyl;
- R 10d is hydrogen; loweralkyl; aryl; or amidino;
- R 11d hydrogen; loweralkyl; cyano; amidino; aryl; aroyl; loweralkanoyl; NHR 13d ;
- R 12d is hydrogen; loweralkyl; halo; aralkyl; amino; cyano; mono- or diloweralkylamino; or OR 4d ;
- R 13d is hydrogen; loweralkyl; or aryl
- R 3d is C 3-8 cycloalkyl and benzofused C 3-8 cycloalkyl; perhydrobenzofused C 3-8 cycloalkyl; aryl;
- R 14d is hydrogen or loweralkyl; and, a pharmaceutically acceptable salt thereof;
- R 1 e is H, allyl, vinyl or the side chain of an optionally protected naturally occurring ⁇ -amino acid
- R 2 e is H, 1-6C alkyl, 2-6C alkonyl or aryl(1-4C alkyl);
- Y e is H or OH and Z e is H, or Y e and Z e together oxygen;
- X e is 1-6C alkyl, 2-6C alkonyl, 5-9C cycloalkyl, 6-
- isoquinoline carboxylic acids which are angiotensin coverting enzyme inhibitors and have the formula
- n f is 0 or 1; is a benzene or cyclohexane ring:
- R 1 f and R 2 f are each 1-6C alkyl, 2-6C alkonyl, 5-7C cycloalkyl, 5-7C cycloalkenyl, 7-12C
- cycloalkylalkyl optionally partially hydrogenated 6-10C aryl, 7-14C aralkyl or 5-7 membered monocyclic or 8-10 membered bicyclic heterocyclyl containing 1 or 2 S or O and/or 1-4N atoms; all R 1 f and R 2 f groups are optionally substituted,
- R 3 f is H, 1-6C alkyl, 2-6C alkonyl or 7-14C aralkyl
- the compounds of the present invention can be produced by methods known to those skilled in the art, for example by one or more of the methods and subroutes described below.
- Reactive groups not involved in the conden ⁇ tions described below e.g., amino, carboxy, etc., may be protected by methods standard in peptide chemistry prior to the coupling reactions and subsequently deprotected to obtain the desired products.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above for Formula I, including suitable
- ketoester (II) can be condensed with the dipeptide (III) in aqueous solution, optimally near neutrality, or in a suitable organic solvent (for example, CH 3 OH) in the presence of a reducing agent such as sodium
- the intermediate Schiff base, enamine, or aminol may be catalytically reduced to yield product I, for example, by hydrogen in the presence of palladium on carbon (e.g. 10% palladium on carbon) or of Raney nickel.
- the ratio of diastereomeric products formed may be altered by choice of catalyst.
- a dipeptide (III) can be alkylated by means of a compound IV:
- X is chloro, bromo, iodo, alkylsulfonyloxy, including haloalkylsulfonyloxy (e.g. CF 3 SO 2 O-) or arylsulfonyloxy.
- the reaction can be carried out under basic conditions in water or in an organic solvent.
- reaction is well known from peptide chemistry.
- the reaction can be carried out in the presence of a
- condensing agent such as dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA) or N,N-disuccinimidyl carbonate in an inert solvent such as CH 3 CN.
- DCC dicyclohexylcarbodiimide
- DPPA diphenylphosphoryl azide
- N,N-disuccinimidyl carbonate in an inert solvent such as CH 3 CN.
- 1-hydroxybenzotriazole its mixed anhydride (derived from a chlorocarbonic acid ester) or its azide.
- the starting compounds in this reaction are known compounds and/or can be prepared according to known methods.
- the compound of formula V can, for example, be prepared by reacting a keto compound II with an amino ester VII: wherein R 8 is an ester protecting group such as t-butyl, according to the conditions described in process A.
- compound V can be prepared by condensing VII and IV:
- These groups can be removed under acidic conditions, e.g. by means of a halogen hydracid and/or trifluoroacetic acid.
- cardiovascular disorders such as congestive heart
- the present invention therefore also relates to treating
- cardiovascular disorders with a carboxyalkyl dipeptide of formula I or with a carboxyalkyl dipeptide of formula I in combination with an ANF or an ACE inhibitor, which methods comprise administering to a mammal in need of such treatment an amount of the carboxyalkyl dipeptide or an amount of a combination of a carboxyalkyl dipeptide and ANF or ACE inhibitor effective to treat hypertension, congestive heart failure, edema or renal insuffiency.
- the drug or combination of drugs is preferably
- a pharmaceutically acceptable carrier e.g. for oral or parenteral administration.
- combinations of drugs may be co-administered in a single composition, or components of the combination therapy may be administered separately. Where the components are administered separately, any convenient combination of dosage forms may be used, e.g. oral carboxyalkyl
- parenteral ACE inhibitor parenteral carboxyalkyl
- dipeptide be administered first.
- the present invention also relates to a
- composition comprising a carboxyalkyl dipeptide for use in treating hypertension, congestive heart failure, edema or renal insufficiency, to a
- composition comprising both a carboxyalkyl dipeptide and an ANF and to a pharmaceutical composition comprising both a carboxyalkyl dipeptide and an ACE inhibitor.
- mice were dosed subcutaneously (1 ml/kg) with vehicle (methylcellulose, hereinafter MC) or carboxyalkyl dipeptide and blood pressure was monitored for the next 4 hours.
- vehicle methylcellulose, hereinafter MC
- carboxyalkyl dipeptides and ACE inhibitors alone and in combination, can be determined as follows:
- Animals are prepared for blood pressure measurement as described above. After stabilization, animals are dosed subcutaneously or orally with test
- enkephalinases designated enkephalinases.
- the compounds are particularly useful for the inhibition of enkephalinase A, which is derived from the striata of both rats and humans.
- enkephalinase A inhibition well known to those skilled in the art, selected compounds having structural formula I have been found to inhibit the activity of the aforementioned enzyme.
- the present invention also relates to a method of inhibiting the action of enkephalinases in a mammal thereby to elicit an analgesic effect with a compound of formula I, and to analgesic pharmaceutical compositions comprising compounds of formula I.
- compositions of this invention comprise a carboxyalkyl dipeptide or a carboxyalkyl dipeptide and an ANF or a carboxyalkyl dipeptide and an ACE inhibitor in combination with a pharmaceutically acceptable carrier for administration to mammals.
- compositions is suitable, preferably for oral or parenteral administration, although mechanical delivery systems such as transdermal dosage forms are also contemplated.
- congestive heart failure, edema or renal insufficiency is as follows: for carboxyalkyl dipeptides alone the typical dosage is 1 to 100 mg/kg of mammalian weight per day administered in single or divided dosages; for the combination of carboxyalkyl dipeptide and an. ANF, the typical dosage is 1 to 100 mg of carboxyalkyl
- dipeptide/kg mammalian weight per day in single or divided dosages plus 0.001 to 0.1 mg ANF/kg of mammalian weight per day, in single or divided dosages, and.for the combination of carboxyalkyl dipeptide and an ACE
- the typical dosage is 1 to 100 mg of
- inhibitor/kg of mammalian weight per day in single or divided dosages.
- the exact dose of any component or combination to be administered is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.
- the compounds or combinations of this invention may be administered to patients in a dosage range as follows: for treatment with carboxyalkyl
- dipeptides alone, about 10 to about 500 mg per dose given 1 to 4 times a day, giving a total daily dose of about 10 to 2000 mg per day; for the combination of carboxyalkyl dipeptide and ANF, about 10 to about 500 mg carboxyalkyl dipeptide per dose given 1 to 4 times a day and about 0.001 to about 1 mg ANF given 1 to 6 times a day (total daily dosage range of 10 to 2000 mg day and .001 to 6 mg/day, respectively); and for the combination of a carboxyalkyl dipeptide and an ACE inhibitor, about 10 to about 500 mg carboxyalkyl dipeptide per dose given 1 to 4 times a day and about 5 to about 50 mg ACE inhibitor given 1 to 3 times a day (total daily dosage range of 10 to 2000 mg/day and 5 to 150 mg/day, respectively). Where the components of a combination are administered
- the number of doses of each component given per day may not necessarily be.the same, e.g. where one component may have a greater duration of activity, and will therefore need to be administered less frequently.
- compounds of this invention will be administered .in a dosage range of from about 1 to about 100 mg/kg.
- the doses are to be administered at intervals of from 3 to 8 hours.
- the quantity and frequency of dosage will depend upon such factors as the severity of the pain, the general physical condition of the patient, the age and weight of the patient, and other factors recognized by the skilled clinician.
- Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions.
- Typical injectable formulations include solutions and
- sugars such as lactose, sucrose, mannitol and sorbitol, starches such as cornstarch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate;
- calcium sufate polyvinylpyrrolidone, polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate, stearic acid.
- vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; non-ionic, cationic and anionic surfactants; ethylene gylcol polymers; beta- cyclodextrin; fatty alcohols and hydrolyzed cereal solids; as well as other nontoxic compatible fillers, binders, disintegrants, buffers, preservatives, anti- oxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations.
- the present invention relates to treatment of hypertension with a combination of active ingredients wherein said active ingredients may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. That is, two kits are contemplated, each combining two separate units: a carboxyalkyl dipeptide
- compositions and an ANF pharmaceutical composition in one kit and a carboxyalkyl dipeptide pharmaceutical composition and an ACE inhibitor
- the kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. oral and parenteral) or are administered at different dosage intervals.
- Step B 2 (R)-Hydroxy-4-Phenylbutyric Acid: At 0°C, treat the product of step A (11.4 g) in methanol (100 ml) with 2N NaOH (52 ml), warm the resulting mixture to room termperature, and stir for 20 hours. Concentrate the reaction mixture in vacuo and partition with water and ethyl acetate. Acidify the aqueous solution with
- Step C 2 (R)-Hydroxy-4-Phenylbutyric Acid Benzyl Ester: Treat the product of step B (9.71 g) in dimethylformamide (85 ml) with cesium carbonate (18.1 g) and benzyl
- Step D 2(R)-Trifluoromethanesulfonyloxy-4-Phenylbutyric Acid Benzyl Ester: At -22°C, add
- dichloromethane Extract the dichloromethane solution with saturated NaHCO 3 solution. Dry (MgSO 4 ) and concentrate the dichloromethane solution in vacuo to obtain a light amber oil.
- Step A 1-(N-Benzyloxycarbonylamino)Cyclopentane-1- Carboxylic Acid t-Butyl Ester: Suspend 1-(N- benzyloxycarbonylamino) cyclopentane-1-carboxylic acid (2.0 g) in dichloromethane (25 ml) in a pressure bottle and cool to 0-5°C. Add concentrated H 2 SO 4 (0.4 ml) and cool to -20°C. Condense isobutylene (10 ml), seal the pressure bottle (20 lb) and stir the reaction mixture at room temperature for 7 days. Pour the reaction mixture into dilute NaOH solution and stir for 10 min. Wash the dichloromethane solution with dilute NaOH and then water. Concentrate the dried (MgSO 4 ) ethyl acetate in vacuo to obtain an oil.
- Step B 1-Aminocyclopentane-1-Carboxylic Acid t-Butyl Ester: Hydrogenate the product of step A (1.8 g) in methanol (30 ml) containing 10% Pd/C (0.30 g) at 50 psi for 6.5 hours. Filter and concentrate the filtrate in vacuo to obtain an oil.
- Step A 1-[1(S)-Benzyloxycarbonyl-3-phenylpropyl]- aminocyclopentane Carboxylic Acid t-Butyl Ester: At 0- 5°C, add a solution of the product of Preparation 2 (2.6 g) and Proton Sponge® (1,8-bis(dimethylamino)naphthalene) (2.0 g.) in dichloromethane (40 ml) (dried over Molecular sieves 4A) dropwise to a solution of the product of
- Step B 1-[1(S)-Benzyloxycarboxyl-3-Phenylpropyl] aminocyclopentane Carboxylic Acid Hydrochloride: Treat the product of step A (3.7 g) in dichloromethane (40 ml) with trifluoroacetic acid (25 ml), and stir the resulting mixture at room temperature for 19 hours. Concentrate the reaction mixture in vacuo, add dichloromethane (20 ml), and concentrate in vacuo. Add excess HCl in
- active compound designates a compound of formula I, preferably N-[1-[1(S)-carboxy-3- phenylpropyl]amino]cyclopentylcarbonyl]-(S)-isoserine.
- this compound may be replaced by equally
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002069312A CA2069312A1 (en) | 1989-10-13 | 1990-10-10 | Carboxyalkyl dipeptide inhibitors of endopeptidases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42104189A | 1989-10-13 | 1989-10-13 | |
US421,041 | 1989-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005796A1 true WO1991005796A1 (en) | 1991-05-02 |
Family
ID=23668944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/005640 WO1991005796A1 (en) | 1989-10-13 | 1990-10-10 | Carboxyalkyl dipeptide inhibitors of endopeptidases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0495822A1 (en) |
JP (1) | JPH05501247A (en) |
AU (1) | AU6503390A (en) |
CA (1) | CA2069312A1 (en) |
WO (1) | WO1991005796A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0527624A2 (en) * | 1991-08-12 | 1993-02-17 | E.R. Squibb & Sons, Inc. | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure |
EP0544620A1 (en) * | 1991-11-26 | 1993-06-02 | Ciba-Geigy Ag | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) |
EP1619189A1 (en) * | 1998-11-12 | 2006-01-25 | Seikagaku Corporation | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513009A (en) * | 1980-04-17 | 1985-04-23 | Societe Civile Bioprojet | Aminoacid derivatives and their therapeutic applications |
US4610816A (en) * | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
EP0254032A2 (en) * | 1986-06-20 | 1988-01-27 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
DE3819539A1 (en) * | 1987-06-08 | 1988-12-22 | Squibb & Sons Inc | INHIBITORS OF NEUTRAL ENDOPEPTIDASE |
-
1990
- 1990-10-10 WO PCT/US1990/005640 patent/WO1991005796A1/en not_active Application Discontinuation
- 1990-10-10 EP EP90914812A patent/EP0495822A1/en not_active Ceased
- 1990-10-10 JP JP2513846A patent/JPH05501247A/en active Pending
- 1990-10-10 AU AU65033/90A patent/AU6503390A/en not_active Abandoned
- 1990-10-10 CA CA002069312A patent/CA2069312A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513009A (en) * | 1980-04-17 | 1985-04-23 | Societe Civile Bioprojet | Aminoacid derivatives and their therapeutic applications |
US4610816A (en) * | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
EP0254032A2 (en) * | 1986-06-20 | 1988-01-27 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
DE3819539A1 (en) * | 1987-06-08 | 1988-12-22 | Squibb & Sons Inc | INHIBITORS OF NEUTRAL ENDOPEPTIDASE |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0527624A2 (en) * | 1991-08-12 | 1993-02-17 | E.R. Squibb & Sons, Inc. | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure |
EP0527624A3 (en) * | 1991-08-12 | 1993-09-15 | E.R. Squibb & Sons, Inc. | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure |
EP0544620A1 (en) * | 1991-11-26 | 1993-06-02 | Ciba-Geigy Ag | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) |
US5244889A (en) * | 1991-11-26 | 1993-09-14 | Ciba-Geigy Corporation | Certain macrocyclic lactam derivatives |
US5426103A (en) * | 1991-11-26 | 1995-06-20 | Ciba-Geigy Corporation | Certain macrocyclic lactam derivatives |
EP1619189A1 (en) * | 1998-11-12 | 2006-01-25 | Seikagaku Corporation | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP0495822A1 (en) | 1992-07-29 |
AU6503390A (en) | 1991-05-16 |
JPH05501247A (en) | 1993-03-11 |
CA2069312A1 (en) | 1991-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5407960A (en) | Mercaptocycloacyl aminoacid endopeptidase inhibitors | |
US5075302A (en) | Mercaptoacyl aminolactam endopeptidase inhibitors | |
US4879309A (en) | Mercapto-acylamino acids as antihypertensives | |
US5232920A (en) | N-(mercaptoalkyl)amides | |
US5389610A (en) | Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors | |
US5173506A (en) | N-(mercaptoalkyl)ureas and carbamates | |
AU633079B2 (en) | Mercapto-acylamino acids | |
WO1991005796A1 (en) | Carboxyalkyl dipeptide inhibitors of endopeptidases | |
WO1989005796A1 (en) | Mercapto-acylamino acid antihypertensives | |
EP0528997B1 (en) | Disulfide derivatives of mercaptoacylamino acids | |
EP0355784A1 (en) | Mercapto-acylamino acid antihypertensives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2069312 Country of ref document: CA Ref document number: 1990914812 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990914812 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1990914812 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990914812 Country of ref document: EP |